Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Multi-Center Study Evaluating the Safety and Efficacy of CD30-Directed Genetically Modified Autologous T Cells (CD30.CAR-T) in Adult and Pediatric Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Next Previous
Search
Trial Profile

A Phase 2 Multi-Center Study Evaluating the Safety and Efficacy of CD30-Directed Genetically Modified Autologous T Cells (CD30.CAR-T) in Adult and Pediatric Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Jan 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TT 11 (Primary) ; Bendamustine; Cyclophosphamide; Fludarabine
  • Indications Hodgkin's disease
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms CHARIOT
  • Sponsors Tessa Therapeutics

    • Most Recent Events

    • 13 Dec 2022 Results(As of 22 July 2022, n=15 from the Pilot segment) assessing safety and efficacy of CD30.CAR-T-Cell Therapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma presented at the 64th American Society of Hematology Annual Meeting and Exposition
    • 13 Dec 2022 Results (As of 22 July 2022, n=17 )presented at the 64th American Society of Hematology Annual Meeting and Exposition
    • 12 Dec 2022 Updated clinical data from the pilot stage of this trial was presented in a Tessa Therapeutics Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top